Zachary L McCormick1, Jeremy Walker2, Benjamin Marshall, Robert McCarthy, David R Walega. 1. The Rehabilitation Institute of Chicago/Northwestern University Feinberg School of Medicine, Department of Physical Medicine and Rehabilitation, USA. 2. Northwestern University Feinberg School of Medicine, Department of Anesthesiology, USA.
Abstract
BACKGROUND: While cooled radiofrequency ablation (C-RFA) appears to be a promising technology for joint denervation, outcomes of this technique for the treatment of lumbar facet syndrome have not been described. We report clinical outcomes in a case series of patients treated with C-RFA for lumbar facet syndrome. METHODS: Consecutive patients aged 18-60 years diagnosed with lumbar facet syndrome, confirmed by ≥75% symptom relief with at least one set of diagnostic medial branch nerve blocks, who underwent C-RFA between January 2007 and December 2013 in an urban academic pain center were included. The respective proportions of participants who reported ≥50% improvement in pain and in function were calculated. Change in median NRS score, daily morphine equivalent consumption (DME), and medication quantification scale III (MQS III) score were measured. RESULTS: Twelve patients underwent C-RFA; three were lost to follow-up. The median and 25%-75% interquartile range (IQR) for age was 44 years (35, 54). The median duration of follow-up was 34 months, IQR (21, 55). The percentage and 95% confidence interval (CI) of patients who reported ≥50% improvement in pain was 33% CI (12%, 64%) and in function was 78%, CI (41%, 96%). There was no significant change in DME or MSQ III score. Approximately 50% of patients sought additional healthcare by long-term follow-up. No complications were reported. CONCLUSIONS: This case series suggests that C-RFA may improve function and to a lesser degree pain at long-term follow-up. A randomized, controlled trial is warranted.
BACKGROUND: While cooled radiofrequency ablation (C-RFA) appears to be a promising technology for joint denervation, outcomes of this technique for the treatment of lumbar facet syndrome have not been described. We report clinical outcomes in a case series of patients treated with C-RFA for lumbar facet syndrome. METHODS: Consecutive patients aged 18-60 years diagnosed with lumbar facet syndrome, confirmed by ≥75% symptom relief with at least one set of diagnostic medial branch nerve blocks, who underwent C-RFA between January 2007 and December 2013 in an urban academic pain center were included. The respective proportions of participants who reported ≥50% improvement in pain and in function were calculated. Change in median NRS score, daily morphine equivalent consumption (DME), and medication quantification scale III (MQS III) score were measured. RESULTS: Twelve patients underwent C-RFA; three were lost to follow-up. The median and 25%-75% interquartile range (IQR) for age was 44 years (35, 54). The median duration of follow-up was 34 months, IQR (21, 55). The percentage and 95% confidence interval (CI) of patients who reported ≥50% improvement in pain was 33% CI (12%, 64%) and in function was 78%, CI (41%, 96%). There was no significant change in DME or MSQ III score. Approximately 50% of patients sought additional healthcare by long-term follow-up. No complications were reported. CONCLUSIONS: This case series suggests that C-RFA may improve function and to a lesser degree pain at long-term follow-up. A randomized, controlled trial is warranted.
Entities:
Keywords:
Denervation; Low back pain; Zygapophyseal joint
Authors: John DeVine; Daniel C Norvell; Erika Ecker; Daryl R Fourney; Alex Vaccaro; Jeff Wang; Gunnar Andersson Journal: Spine (Phila Pa 1976) Date: 2011-10-01 Impact factor: 3.468
Authors: M E Revel; V M Listrat; X J Chevalier; M Dougados; M P N'guyen; C Vallee; M Wybier; F Gires; B Amor Journal: Arch Phys Med Rehabil Date: 1992-09 Impact factor: 3.966
Authors: Zachary L McCormick; Heejung Choi; Rajiv Reddy; Raafay H Syed; Meghan Bhave; Mark C Kendall; Dost Khan; Geeta Nagpal; Masaru Teramoto; David R Walega Journal: Reg Anesth Pain Med Date: 2019-03 Impact factor: 6.288